FDA again extends review of Pfizer's Prevnar 13

12/30/2009 | Wall Street Journal, The · Yahoo!

Pfizer announced that the FDA has not completed its review of Prevnar 13, a new version of its vaccine for pneumococcal disease in children. The agency had also rescheduled its approval decision on the product in August. A company official said Pfizer remains confident in its application for Prevnar 13 despite the delays.

View Full Article in:

Wall Street Journal, The · Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC